Kerstin Piayda, Julian Tim Heilemann, Stanislav Keranov, Luisa Schulz, Mani Arsalan, Christoph Liebetrau, Won-Keun Kim, Felix J Hofmann, Pascal Bauer, Sandra Voss, Christian Troidl, Samuel T Sossalla, Christian W Hamm, Holger M Nef, Oliver Dörr
Background: Currently available risk scores fail to accurately predict morbidity and mortality in patients with severe symptomatic aortic stenosis who undergo transcatheter aortic valve implantation (TAVI). In this context, biomarkers like matrix metalloproteinase-2 (MMP-2) and galectin-3 (Gal-3) may provide additional prognostic information. Methods: Patients with severe aortic stenosis undergoing consecutive, elective, transfemoral TAVI were included. Baseline demographic data, functional status, echocardiographic findings, clinical outcomes, and biomarker levels were collected and analyzed...
April 8, 2024: Biomarkers: Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals